Esmolol , rather than nicardipine , increased minimal lumen diameter ( P = 0.040 ) , prolonged SFT ( 0.34 0.03 s vs. 0.41 0.03 s , P < 0.001 ) , reduced DCP ( P < 0.001 ) and increased blood velocity ( 33.65 1.07 cm/s vs. 43.36 1.25 cm/s , P < 0.001 ) at SFT stages , with increased blood-flow ( P < 0.001 ) .
